Verily secured $300 million in outside capital that ends Alphabet’s controlling stake in the healthcare innovation company, the firm announced. The financing—led by Series X Capital with other investors—repositions Verily as an independent growth-stage company with an expanded investor base and a new governance structure. Verily will use the proceeds to scale commercialization of digital health tools, diagnostics and clinical platforms. For industry readers: Verily’s pivot away from majority Alphabet ownership could accelerate commercial partnerships and licensing deals with life‑science partners that previously hesitated due to corporate parent dynamics. The deal reflects continued private investment appetite for health‑tech firms with differentiated data assets, but it raises questions about how Verily will balance product commercialization with long‑term research commitments previously underwritten by Alphabet.